Enhertu cancer drug shows enduring results in ongoing clinical trial
The latest results from a Phase II clinial trial into Enhertu shows consistently promising results, with a durable response in patients with various HER2-expressing tumours.
At the beginning of the year, we highlighted Enhertu from AstraZeneca and Daiichi Sankyo as one of the biggest drug approvals of 2022 and to watch for the year ahead, with promising results from early trials.
Now, further results have been released from the DESTINY-PanTumor02 Phase II trial, looking into the efficacy of the drug, which has shown a positive and durable response in patients with multiple HER2-expressing advanced solid tumours.
The trial includes patients with locally advanced, unresectable, or metastatic previously-treated, HER2-expressing solid tumours that are not eligible for curative therapy. This spans biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, and rare cancers.
Enhertu (trastuzumab deruxtecan) is an engineered HER2-directed antibody drug conjugate (ADC), which targets the HER2 tyrosine kinase receptor protein expressed on the surface of certain cells. The protein is involved in normal cell growth, but in cancer cells it can be overexpressed.
The DESTINY-PanTumor02 Phase II trial aims to evaluate the efficacy and safety of Enhertu as a HER2-targeted therapy. Currently, the safety profile of the drug is consistent with other similar trials. The data from the trial is due to be presented at upcoming meetings and submitted to relevant regulatory agencies for further evaluation.
“Enhertu has already demonstrated its potential to improve outcomes for patients with HER2-targetable breast, gastric and lung cancers, and these positive initial results in other tumour settings with significant unmet need are very encouraging. The DESTINY-PanTumor02 results mark an important step forward in our understanding of the potential role of Enhertu across multiple HER2-expressing tumour types.” Stated Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca.
Ken Takeshita, Global Head, R&D of Daiichi Sankyo, added: “The clinically meaningful responses seen in the DESTINY-PanTumor02 trial reaffirm our belief in the potential of Enhertu across multiple HER2-expressing cancers. The results seen so far across multiple cohorts of the trial will inform next steps of our broad development programme as we look to bring this important medicine to as many patients as quickly as possible.”
Related News
-
News Pharma CEOs write open letter calling suppliers to commit to sustainability
Several big pharma companies have added their names to a letter challenging suppliers in the healthcare industry to pledge to sustainability targets. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed. -
News Ardena forms partnership with RiboPro to improve mRNA-based therapies
Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape. -
News Humira biosimilars at discounted prices to meet market demand for accessible treatment
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News Women in Pharma: Gearing up for systemic change
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Delivering on mRNA-based therapeutics: innovations in applications and packaging
Since the onset of the COVID-19 pandemic, the innovative potential of mRNA vaccines and therapeutics has raised questions regarding their manufacturing, packaging, and storage/transportation. Learn about how the pharmaceutical supply chain is meet... -
News Your Prescription for Marketing Success: Digital Pharma Marketing Toolkit – Free eBook
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance